FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Advanced RNA Technologies, LLC 		2. Issuer Name and Ticker or Trading Symbol

RXi Pharmaceuticals Corp [ RXII ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

1 KENDALL SQUARE BUILDING 200, SUITE 2203 		3. Date of Earliest Transaction (MM/DD/YYYY)

2/20/2014
(Street)

CAMBRIDGE, MA 02139
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.0001 par value   2/20/2014     J (1)    1200   D $4.7   1294377   (2) D    
Common Stock, $0.0001 par value   2/21/2014     J (1)    5641   D $4.75   1288736   D    
Common Stock, $0.0001 par value   2/21/2014     J (1)    2900   D $4.735   1285836   D    
Common Stock, $0.0001 par value   2/21/2014     J (1)    2100   D $4.71   1283736   D    
Common Stock, $0.0001 par value   2/21/2014     J (1)    576   D $4.8   1283160   D    
Common Stock, $0.0001 par value   2/21/2014     J (1)    5000   D $5.15   1278160   D    
Common Stock, $0.0001 par value   2/21/2014     J (1)    5000   D $4.85   1273160   D    
Common Stock, $0.0001 par value   2/21/2014     J (1)    5000   D $5   1268160   D    
Common Stock, $0.0001 par value   2/24/2014     J (1)    1575   D $6.3   1266585   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Sales of non-derivative securities sold in the manner required under Rule 144.
( 2)  As reported on the Issuer's 8-K filed on July 23, 2013, on July 19, 2013, the Issuer filed with the Secretary of State of the STate of Delaware a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a one-for-thirty reverse stock split of the Issuer's issued and outstanding common stock, par value $0.0001 per share on July 23, 2013 at 11:59 p.m. Eastern Time. Accordingly, the number of shares beneficially owned by the Reporting Person takes this reverse stock split into account.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Advanced RNA Technologies, LLC
1 KENDALL SQUARE BUILDING 200
SUITE 2203
CAMBRIDGE, MA 02139
X


Signatures
Alexey Wolfson 3/6/2014
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more RXI Pharmaceuticals Corporation Charts.
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more RXI Pharmaceuticals Corporation Charts.